Difference between revisions of "Busulfan (Myleran)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(updated content)
m
 
(46 intermediate revisions by 6 users not shown)
Line 1: Line 1:
−
Also known as Busulfex.
 
−
 
 
==General information==
 
==General information==
−
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.<ref name="insert">[http://www.pharmgkb.org/clinical/16515283.pdf Busulfan (Myleran) package insert]</ref><ref>[[Media:Busulfan.pdf | Busulfan (Myleran) package insert (locally hosted backup)]]</ref>
+
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf456fc7-3a79-47f7-8acc-600b5e2f0dc2 Busulfan (Myleran) package insert]</ref><ref>[[:File:Busulfan.pdf | Busulfan (Myleran) package insert (locally hosted backup)]]</ref><ref>[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf456fc7-3a79-47f7-8acc-600b5e2f0dc2 Busulfan (Busulfex) package insert]</ref><ref>[[:File:Busulfanbusulfex.pdf | Busulfan (Busulfex) package insert (locally hosted backup)]]</ref>
−
<br>Route: IV
+
<br>Route: IV, PO
 
<br>Extravasation: [[irritant]]
 
<br>Extravasation: [[irritant]]
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/myleran-busulfex-busulfan-342104 Medscape],[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
−
*[[Bone cancer]]
+
*[[Acute myeloid leukemia]]
 +
*[[Acute promyelocytic leukemia]]
 +
*[[Chronic lymphocytic leukemia]]
 +
*[[Chronic myeloid leukemia]]
 +
*[[Ewing sarcoma]]
 +
*Non-Hodgkin lymphoma
 +
**[[Anaplastic large cell lymphoma]]
 +
**[[CNS lymphoma]]
 +
**[[Diffuse large B-cell lymphoma]]
 +
**[[Mantle cell lymphoma]]
 +
**[[NK- and T-cell lymphoma]]
 +
**[[Peripheral T-cell lymphoma]]
 +
**[[Primary mediastinal B-cell lymphoma]]
 +
*[[Myelodysplastic syndrome]]
 +
*[[Neuroblastoma]]
 +
 
 +
==Diseases for which it was used==
 +
*[[Multiple myeloma - historical|Multiple myeloma]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://chemocare.com/chemotherapy/drug-info/busulfan.aspx Busulfan (Myleran) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/busulfan.aspx Busulfan (Myleran) patient drug information (Chemocare)]</ref>
+
*[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf456fc7-3a79-47f7-8acc-600b5e2f0dc2 Busulfan (Myleran) package insert]<ref name="insert"></ref>
 +
*[https://chemocare.com/druginfo/busulfan.aspx Busulfan (Myleran) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/busulfan.aspx Busulfan (Myleran) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/busulfan-patient-drug-information Busulfan (Myleran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/busulfan-patient-drug-information Busulfan (Myleran) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/busulfan-patient-drug-information Busulfan (Myleran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/busulfan-patient-drug-information Busulfan (Myleran) patient drug information (UpToDate)]</ref>
 +
 +
==History of changes in FDA indication==
 +
* 1954-06-26: Initial FDA approval
 +
*2003-01-23 (oldest label available at Drugs @ FDA): indicated for the palliative treatment of [[Chronic myeloid leukemia|chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia]]. ''(No supporting studies are cited)''
 +
==History of changes in EMA indication==
 +
*2003-07-09: EURD
 +
==History of changes in PMDA indication==
 +
*2020-03-25: New indication and a new dosage for the conditioning treatment of malignant lymphoma in patients prior to autologous hematopoietic stem-cell transplantation.
 +
==Also known as==
 +
*'''Brand names:''' Busilvex, Busulfex, Myleran
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drugs]]
 +
[[Category:Oral medications]]
 +
[[Category:Intravenous medications]]
 +
[[Category:Alkyl sulfonates]]
 +
[[Category:Irritant]]
 +
 +
[[Category:Acute myeloid leukemia medications]]
 +
[[Category:Acute promyelocytic leukemia medications]]
 +
[[Category:Anaplastic large cell lymphoma medications]]
 +
[[Category:Chronic lymphocytic leukemia medications]]
 +
[[Category:Chronic myeloid leukemia medications]]
 +
[[Category:CNS lymphoma medications]]
 +
[[Category:Diffuse large B-cell lymphoma medications]]
 +
[[Category:Ewing sarcoma medications]]
 +
[[Category:Mantle cell lymphoma medications]]
 +
[[Category:Myelodysplastic syndrome medications]]
 +
[[Category:Neuroblastoma medications]]
 +
[[Category:NK- and T-cell lymphoma medications]]
 +
[[Category:Peripheral T-cell lymphoma medications]]
 +
[[Category:Primary mediastinal B-cell lymphoma medications]]
 +
[[Category:Multiple myeloma medications (historic)]]
 +
 +
[[Category:FDA approved in 1954]]
 +
[[Category:EMA approved in 2003]]

Latest revision as of 16:41, 13 September 2023

General information

Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.[1][2][3][4]
Route: IV, PO
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2003-07-09: EURD

History of changes in PMDA indication

  • 2020-03-25: New indication and a new dosage for the conditioning treatment of malignant lymphoma in patients prior to autologous hematopoietic stem-cell transplantation.

Also known as

  • Brand names: Busilvex, Busulfex, Myleran

References

  1. ↑ 1.0 1.1 1.2 Busulfan (Myleran) package insert
  2. ↑ Busulfan (Myleran) package insert (locally hosted backup)
  3. ↑ Busulfan (Busulfex) package insert
  4. ↑ Busulfan (Busulfex) package insert (locally hosted backup)
  5. ↑ Busulfan (Myleran) patient drug information (Chemocare)
  6. ↑ Busulfan (Myleran) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Busulfan_(Myleran)&oldid=77674"